174 related articles for article (PubMed ID: 28849180)
1. Silencing Aurora A leads to re-sensitization of breast cancer cells to Taxol through downregulation of SRC-mediated ERK and mTOR pathways.
Li Y; Zhou W; Tang K; Chen X; Feng Z; Chen J
Oncol Rep; 2017 Oct; 38(4):2011-2022. PubMed ID: 28849180
[TBL] [Abstract][Full Text] [Related]
2. Function of Aurora kinase A in Taxol-resistant breast cancer and its correlation with P-gp.
Li Y; Tang K; Zhang H; Zhang Y; Zhou W; Chen X
Mol Med Rep; 2011; 4(4):739-46. PubMed ID: 21584498
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
[TBL] [Abstract][Full Text] [Related]
5. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
6. Timosaponin AIII, a steroidal saponin, exhibits anti-tumor effect on taxol-resistant cells in vitro and in vivo.
Song XY; Han FY; Chen JJ; Wang W; Zhang Y; Yao GD; Song SJ
Steroids; 2019 Jun; 146():57-64. PubMed ID: 30951756
[TBL] [Abstract][Full Text] [Related]
7. Astragaloside IV enhances taxol chemosensitivity of breast cancer via caveolin-1-targeting oxidant damage.
Zheng Y; Dai Y; Liu W; Wang N; Cai Y; Wang S; Zhang F; Liu P; Chen Q; Wang Z
J Cell Physiol; 2019 Apr; 234(4):4277-4290. PubMed ID: 30146689
[TBL] [Abstract][Full Text] [Related]
8. The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.
D'Assoro AB; Liu T; Quatraro C; Amato A; Opyrchal M; Leontovich A; Ikeda Y; Ohmine S; Lingle W; Suman V; Ecsedy J; Iankov I; Di Leonardo A; Ayers-Inglers J; Degnim A; Billadeau D; McCubrey J; Ingle J; Salisbury JL; Galanis E
Oncogene; 2014 Jan; 33(5):599-610. PubMed ID: 23334326
[TBL] [Abstract][Full Text] [Related]
9. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
[TBL] [Abstract][Full Text] [Related]
10. Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality.
Zhang W; Xia D; Li Z; Zhou T; Chen T; Wu Z; Zhou W; Li Z; Li L; Xu J
Cell Death Dis; 2019 Aug; 10(8):606. PubMed ID: 31406104
[TBL] [Abstract][Full Text] [Related]
11. Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.
Hole S; Pedersen AM; Lykkesfeldt AE; Yde CW
Breast Cancer Res Treat; 2015 Feb; 149(3):715-26. PubMed ID: 25667100
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
13. ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.
Thollet A; Vendrell JA; Payen L; Ghayad SE; Ben Larbi S; Grisard E; Collins C; Villedieu M; Cohen PA
Mol Cancer; 2010 Nov; 9():291. PubMed ID: 21059223
[TBL] [Abstract][Full Text] [Related]
14. Gallic acid abolishes the EGFR/Src/Akt/Erk-mediated expression of matrix metalloproteinase-9 in MCF-7 breast cancer cells.
Chen YJ; Lin KN; Jhang LM; Huang CH; Lee YC; Chang LS
Chem Biol Interact; 2016 May; 252():131-40. PubMed ID: 27087131
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells.
Shi Y; Gong W; Lu L; Wang Y; Ren J
Braz J Med Biol Res; 2019; 52(11):e8657. PubMed ID: 31664305
[TBL] [Abstract][Full Text] [Related]
16. [Effect of sodium aescinate in inducing human breast cancer MCF-7 cells apoptosis by inhibiting AKT, ERK and upstream signal SRC activity].
Qi SM; Lv J; Meng Y; Qi ZL; Ling LF
Zhongguo Zhong Yao Za Zhi; 2015 Aug; 40(16):3267-72. PubMed ID: 26790305
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
19. Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3.
Ao X; Nie P; Wu B; Xu W; Zhang T; Wang S; Chang H; Zou Z
Cell Death Dis; 2016 Nov; 7(11):e2463. PubMed ID: 27831559
[TBL] [Abstract][Full Text] [Related]
20. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Thrane S; Pedersen AM; Thomsen MB; Kirkegaard T; Rasmussen BB; Duun-Henriksen AK; Lænkholm AV; Bak M; Lykkesfeldt AE; Yde CW
Oncogene; 2015 Aug; 34(32):4199-210. PubMed ID: 25362855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
